MITS - SR Component

分子和免疫翻译科学(MITS)--项目摘要 MITS共享资源是研究癌症和癌症动物模型的门户 具有一套技术和分析技术的人类衍生材料，使弗吉尼亚大学癌症大学 UVACC中心(UVACC)成员评估研究试剂对诊断或治疗糖尿病的影响 癌症。MITS允许专家对符合以下条件的实验进行计划、培训、执行和分析 在此共享资源和其他UVAcc中提供的最先进的工具上运行- 支持的共享资源。MITS仪器位于便于UVACC成员使用的位置。 仪器由专业技术人员在正常工作时间运行，可由 调查人员在完成适当的培训后，在非黄金时段工作。这是共享的 资源是疾病核心动物模型的扩展，在过去的几年中被评为优秀 复习一下。上次审查针对CRISPR-CAS9利用情况的资源的次要意见 取代传统基因打靶以创造条件基因敲除和敲入等位基因的技术已经 已经解决了。MITS在过去五年中进行了重大的设备升级，并深化了 研究人员可获得的患者来源的异种移植物(PDX)曲目。ITS的工作人员经常与其他人互动 UVACC共享资源，特别是生物分子分析设备、生物统计学、高级显微镜 设施，流式细胞仪核心，以及生物库和组织研究设施，所有这些都有助于使MITS成为 Nexus用于高度协调和高效的临床前和临床研究。MITS也得到了学校的支持 医学部(SOM)，进一步降低了UVACC用户的成本。MITS每年由 UVACC领导层和高官管理研究咨询委员会确定所需补贴水平 保持收入中性的核心。MITS在价格上具有竞争力，服务周转时间快，并提供 保证达到或超过国家可比较共享资源设定的标准。这个 UVACC为会员提供的自付费用使MITS成为一种经济高效的共享资源。

MOLECULAR AND IMMUNOLOGICAL TRANSLATIONAL SCIENCES (MITS) – PROJECT SUMMARY The MITS Shared Resource serves as a gateway for the study of both animal models of cancer and human-derived materials with a suite of skills and analytical techniques that allow University of Virginia Cancer Center (UVACC) Members to evaluate the impact of investigational agents on the diagnosis or treatment of cancer. MITS provides access to experts for planning, training, executing, and analyzing experiments that are run on state-of-the-art instrumentation within this Shared Resource and those available in other UVACC- supported Shared Resources. MITS instrumentation is located for easy access by UVACC Members. Instrumentation is run by expert technologists during normal working hours and is available for use by investigators during non-primetime hours once they have completed appropriate training. This Shared Resource is an expansion of the Animal Models of Disease Core, which was rated as Excellent during the last review. Minor comments from the previous review of the resource directed at the utilization of CRISPR-Cas9 technology to replace traditional gene targeting for creating conditional knockout and knock-in alleles have been addressed. MITS made significant equipment upgrades in the past five years and deepened the repertoire of patient-derived xenografts (PDX) available to researchers. MITS staff routinely interact with other UVACC Shared Resources, particularly the Biomolecular Analysis Facility, Biostatistics, Advanced Microscopy Facility, Flow Cytometry Core, and Biorepository and Tissue Research Facility, all of which help make MITS a nexus for highly-coordinated and efficient pre-clinical and clinical studies. MITS also is supported by the School of Medicine (SOM), which further lowers the cost for the UVACC users. MITS is reviewed annually by the UVACC leadership and the SOM Research Advisory Committee to determine the level of subsidy required to maintain a revenue neutral core. MITS is competitive in pricing, rapid in service turnout time, and provides guarantees matching or exceeding the standards set up by comparative shared resources nationally. The UVACC co-pay provided for Members makes MITS a cost-effective Shared Resource.